Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents

医学 内科学 化疗 肿瘤科 心力衰竭 癌症 优势比 倾向得分匹配 置信区间 紫杉烷 乳腺癌
作者
Tomiko Sunaga,Takahiro Okada,Yoshitaka Iso,Mio Ebato,Tsutomu Toshida,Shuichi Nawata,Hiroshi Suzuki,Mari Kogo
出处
期刊:Esc Heart Failure [Wiley]
卷期号:12 (3): 1965-1976 被引量:1
标识
DOI:10.1002/ehf2.15204
摘要

Abstract Background The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio‐oncology has received increasing attention owing to the cardiotoxic effects of anti‐cancer therapies. Objectives We aimed to evaluate the clinical characteristics and outcomes of patients with heart failure (HF) who received chemotherapy compared with those of a matched cohort with HF who did not receive chemotherapy, using real‐world HF data. Methods This study was based on the Diagnosis Procedure Combination (DPC) database of the Japanese Registry of All Cardiac and Vascular Diseases (JROAD). We identified 1 328 113 patients who were hospitalized for HF between April 2012 and March 2021. The propensity score (PS) was estimated using a logistic regression model, with chemotherapy as the dependent variable, and a clinically score‐matched analysis of 11 532 patients with HF with or without chemotherapy. The primary endpoint was readmission. Results Colon, lung, breast and prostate cancers accounted for >60% of all cancer types. After PS matching, readmission was significantly more frequently observed in patients with chemotherapy than those without [odds ratio (OR), 1.26; 95% confidence interval (CI) 1.17–1.36, P < 0.01]. In particular, treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) (OR, 1.69; 95% CI 1.39–2.07), taxane (OR, 2.95; 95% CI 2.11–4.12), anthracyclines (OR, 1.86; 95% CI 1.19–2.90) and fluorouracil agents (OR, 1.65; 95% CI 1.18–2.30) caused a higher risk of readmission. Conclusions Medical providers need to monitor and follow‐up patients with HF, depending on the characteristics of the anti‐cancer agents and types of cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er的应助被火星猎人采纳,获得10
1秒前
浅唱夏末发布了新的文献求助10
1秒前
黑米粥发布了新的文献求助200
1秒前
1秒前
FashionBoy的应助被尼克采纳,获得10
4秒前
4秒前
4秒前
Mhh发布了新的文献求助10
5秒前
5秒前
领导范儿的应助被dde采纳,获得10
5秒前
笑然发布了新的文献求助10
7秒前
982289172发布了新的文献求助10
7秒前
大宝宝完成签到 ,获得积分10
7秒前
8秒前
田様的应助被houyushen采纳,获得10
8秒前
8秒前
8秒前
dcc1234完成签到,获得积分10
8秒前
歪歪发布了新的文献求助10
10秒前
奋斗的凡完成签到,获得积分10
10秒前
11秒前
果果完成签到,获得积分10
11秒前
11秒前
11秒前
jie_e完成签到,获得积分10
11秒前
12秒前
nicoleJ发布了新的文献求助10
12秒前
比奇堡探险完成签到 ,获得积分10
13秒前
淡淡班完成签到 ,获得积分10
13秒前
囧囧的应助被吃不饱采纳,获得30
13秒前
万能图书馆的应助被刀河王采纳,获得10
14秒前
贺知什么书完成签到,获得积分10
14秒前
桃子发布了新的文献求助10
15秒前
Holder发布了新的文献求助10
15秒前
15秒前
xiaoh发布了新的文献求助10
15秒前
黑米粥发布了新的文献求助200
16秒前
山大琦子完成签到,获得积分10
16秒前
vvvvyl发布了新的文献求助10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187572
求助须知:如何正确求助?哪些是违规求助? 9575676
关于积分的说明 21842241
捐赠科研通 7785368
什么是DOI,文献DOI怎么找? 3435022
关于科研通互助平台的介绍 2559428
邀请新用户注册赠送积分活动 2481917